Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 3Phase 3 1Phase 1/2 1

Status

Completed 5Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 61Sarcoma 36Breast 29Other hematologic neoplasm 26Gynecologic 16Gastrointestinal 14Other solid neoplasm 13CNS 10Genitourinary 9Tumor-Agnostic 6Thoracic 5Plasma cell 5Dermatologic 5Myeloid 4Endocrine 2Classical hematology 2NET 1Head & Neck 1

Conditions

Neoplasms 4Neoplasm Metastasis 2

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Doxorubicin × Tumor-Agnostic × Clear all
NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
38 enrolled
Tumor-Agnostic

Neoplasms

NCT02483247 2023-11-14

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
165 enrolled
Tumor-Agnostic

Neoplasms

NCT02377752 2021-02-17

A Study of Olaratumab in Japanese Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
25 enrolled 19 charts
Tumor-Agnostic

Neoplasms

NCT02677116 2020-05-20

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

Eli Lilly and Company

Phase 1 Completed
68 enrolled 26 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT00305084 2019-10-04

Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

AGC Biologics S.p.A.

Phase 1 Completed
15 enrolled 20 charts
Tumor-Agnostic

Neoplasms

NCT00798252 2015-07-07

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Bristol-Myers Squibb

Phase 1 Completed
111 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡